2022 World Conference on Lung Cancer (ePosters)-EP08.01-012. First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience

EP08.01-012. First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience

Back to course

Pdf Summary

This study aimed to evaluate the real-world experience of using first-line chemo-immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) patients with PD-L1 expression between 0-49%. The combination of immune checkpoint inhibitors (ICIs) and chemotherapy is the standard of care for these patients without targetable mutations and PD-L1 expression of 50% or higher. The study analyzed data from 162 patients treated at multiple centers in Italy between January 2020 and November 2021.<br /><br />The majority of patients included in the study were male, former or current smokers, and had an Eastern Cooperative Oncology Group Performance Status (PS) of 1. Most patients had adenocarcinoma and presented with extra-thoracic disease. The best response rate was disease control in 75.9% of patients.<br /><br />The median follow-up was 8.1 months. Progression-free survival (PFS) was 11.76 months, and overall survival (OS) was 15.05 months. Forty-seven patients (29.4%) experienced immune-related adverse events (irAEs), with diarrhea being the most common. The development of irAEs was associated with a lower risk of disease progression. PFS and OS were longer in patients who experienced irAEs, had an ECOG PS of 0, had fewer metastatic sites, and did not have liver or bone metastases.<br /><br />The combination of ICI and chemotherapy as first-line therapy in NSCLC patients with PD-L1 expression between 0-49% showed efficacy and safety in a real-world setting. The development of irAEs was associated with a lower risk of disease progression and was a favorable prognostic factor for survival.<br /><br />In conclusion, this study provides real-world evidence supporting the use of first-line chemo-immunotherapy in advanced NSCLC patients with PD-L1 expression between 0-49%. The combination therapy showed efficacy and safety, and the development of irAEs had a favorable impact on survival outcomes.

Asset Subtitle

Beatrice Benetti

Meta Tag

Speaker Beatrice Benetti

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

chemo-immunotherapy

advanced non-small cell lung cancer

PD-L1 expression

immune checkpoint inhibitors

chemotherapy

real-world experience

disease control

progression-free survival

overall survival

immune-related adverse events